Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

BioNTech SE ADR buy zonthiii

Start price
€76.21
18.11.20
Target price
€95.00
Performance (%)
23.96%
Price
€94.31
11:15
This prediction is currently active. The BUY prediction by zonthiii currently has a performance of 23.96%.

According to zonthiii what are the pros and cons of BioNTech SE ADR for the foreseeable future?

Pros
Could be worthwhile Investment >10% per year
Revenue growth > 30% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Capable Management
Differentiated customer and product portfolio
Growths faster than the competition
Top 10 in its market
Very Future proof/growth oriented business model
Cons
Low dividend yield expected
negative Cash Flow expected
Significant cyclical dependencies

Comments by zonthiii for this prediction

In the thread Biontech SE diskutieren
Published 18.11.20
Prediction Buy
Perf. (%) 23.96%
Target price 80.000
Change

Pfizer announced: "[...] that the Phase 3 study of our #COVID19 vaccine candidate has met all primary efficacy endpoints. The study reached 170 confirmed cases of #COVID19, with the #vaccine candidate BNT162b2 demonstrating 95% efficacy beginning 28 days after the first dose"


Published 23.11.20
Prediction Buy
Perf. (%) 23.96%
Target price 95.000
Change

Kursziel geändert auf 95,0

Stopped prediction by zonthiii for BioNTech SE ADR

BioNTech SE ADR

Start price
Target price
Perf. (%)
€74.64
€70.00
2.10%

Could be worthwhile Investment >10% per year
Revenue growth > 30% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
buy
BioNTech SE ADR

Start price
Target price
Perf. (%)
€85.01
€85.00
-12.20%

Could be worthwhile Investment >10% per year
Revenue growth > 30% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group